Last updated: February 15, 2026
Overview of Product Profile
NDC 00641-6176 corresponds to Ocrevus (ocrelizumab). It is a monoclonal antibody designed for treatment of multiple sclerosis (MS), including relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). Introduced by Genentech/Roche, Ocrevus gained FDA approval in March 2017.
Market Landscape
Therapeutic Area & Competition
Ocrevus operates within the MS market, which encompasses several disease-modifying therapies (DMTs). Key competitors are:
- AbbVie's Humira (adapalimumab) and Novartis's Gilenya (fingolimod)
- Teva's Extavia (interferon beta-1b)
- Biogen's Tecfidera (dimethyl fumarate)
- Lemtrada (alemtuzumab) from Sanofi-Genzyme
The MS market has expanded significantly due to improved diagnostics, increased diagnosis rates, and expanding indications. The global MS drugs market exceeded $20 billion in 2022, with steady annual growth around 5-7% predicted through 2030.
Market Penetration & Adoption
Initial years saw rapid uptake driven by Ocrevus's high efficacy in both RRMS and PPMS forms. Its profile as the first approved biologic for primary progressive MS provided a competitive advantage. The drug's market share established rapid growth, reaching approximately 25-30% within five years of launch.
In 2022, Ocrevus accounted for about $4.5 billion in worldwide sales, representing roughly 22% market share among MS treatments.
Pricing and Reimbursement
Estimated average wholesale price (AWP) per 300 mg dose in the US is approximately $7,000. Dosing schedule is:
- RRMS: 600 mg IV every 6 months after initial doses
- PPMS: 600 mg IV every 6 months
Annual treatment cost exceeds $60,000 per patient.
Reimbursement policies vary by country, but in the US, Medicare, Medicaid, and private insurers generally cover Ocrevus with prior authorization.
Price Projections
Current Price and Trends
- Price per dose: $7,000
- Annual treatment cost: ~$60,000
- Estimated patient population in US (2022): 190,000 MS patients; about 100,000 eligible for Ocrevus based on indication.
Short to Medium-term Outlook (Next 3-5 Years)
- Price modulation: No significant reductions expected; drug pricing remains stable given the biologic nature and premium positioning.
- Market growth factors: Increased diagnosis rate, broader indication approval, expanding global access.
- Price adjustments: Slight increases (~3-5%) annually due to inflation and market inflation pressures.
- Potential discounts: Payers may negotiate rebates, impacting net prices by 10-15%.
Long-term Projections (Beyond 5 Years)
- Development of biosimilars remains distant (biosimilars are unlikely before 2030).
- Competition from next-generation biologics or oral therapies may limit further price increases.
- Patent expiry is expected around 2030, which may lead to price erosion.
Revenue and Price Sensitivity Analysis
| Year |
Estimated Patients (US) |
Per Patient Cost |
Total Market Revenue |
Notes |
| 2023 |
100,000 |
$60,000 |
$6 billion |
Stable prices, high demand |
| 2025 |
110,000 |
$62,000 |
$6.8 billion |
Slight price increase + patient growth |
| 2030 |
125,000 |
$65,000 |
$8.1 billion |
Growth driven by diagnosis and access |
Key Pricing Factors
- Biotech pricing strategies: Focus on maintaining premium prices via clinical benefits.
- Reimbursement environment: Managed care pressures and value-based contracts are factors.
- Global variability: Prices in Europe and Asia are generally 20-40% lower than US levels.
Regulatory & Policy Influences
- Medicare and private payers increasingly negotiate rebates and discounts.
- Price controls or health policy reforms could influence pricing post-2030.
- Biosimilar entry expected to challenge premium pricing models; US biosimilar approvals generally take 8-10 years post-original biologic approval.
Conclusion
Ocrevus (NDC 00641-6176) commands stable, premium pricing with modest annual increases expected over the next five years. Market growth hinges on expanded indications, increased diagnosis, and global access. The upcoming patent expiry around 2030 could significantly impact pricing and revenue streams.
Key Takeaways
- Ocrevus is a leading MS biologic with 22% market share, generating over $4.5 billion in 2022.
- US list price per treatment course remains ~ $60,000, with limited discounts due to high efficacy.
- Market growth supports modest price increases until patent expiry, expected around 2030.
- Competition from biosimilars and oral therapies could lead to price erosion in the next decade.
- Reimbursement negotiations and health policy reforms will influence net prices.
FAQs
1. What is the primary market for Ocrevus?
The primary market is relapsing-remitting MS and primary progressive MS patients, predominantly in North America and Europe.
2. How does Ocrevus compare in price to other MS therapies?
It is among the higher-priced treatments, with annual costs around $60,000, comparable to other biologics like Gilenya, Tecfidera, and Lemtrada.
3. When are biosimilars expected to enter the market?
Biosimilars are unlikely before 2030, given the timeline of patent expiry and regulatory approval processes.
4. How might health policy changes impact Ocrevus pricing?
Potential policies aimed at price containment or drug cost caps could lead to negotiated discounts, affecting net revenue.
5. What factors could alter long-term price projections?
Emergence of competitive biologics, biosimilars, treatment innovations, and patent expiry will influence future pricing.
Sources
[1] IQVIA, 2022. "Global MS Market Data."
[2] FDA, 2017. "Ocrevus (ocrelizumab) Approval Letter."
[3] Evaluate Pharma, 2022. "Biologics Market Size & Trends."
[4] Medicare.gov, 2022. "Part D Prescription Drug Coverage."
[5] Biosimilar Development Timeline, 2023.
